PA
PTCT icon

Profund Advisors’s PTC Therapeutics PTCT Stock Holding History

Profund Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
22,973
-10,353
-31% -$748K 0.05% 211
2026
Q1 		$2.27M Buy
33,326
+1,473
+5% +$104K 0.08% 175
2025
Q4 		$2.42M Buy
31,853
+9,591
+43% +$697K 0.07% 177
2025
Q3 		$1.37M Buy
22,262
+1,420
+7% +$74K 0.04% 264
2025
Q2 		$1.02M Buy
20,842
+8,131
+64% +$386K 0.04% 299
2025
Q1 		$648K Sell
12,711
-3,325
-21% -$166K 0.03% 405
2024
Q4 		$724K Sell
16,036
-4,710
-23% -$202K 0.03% 369
2024
Q3 		$770K Buy
20,746
+1,388
+7% +$46.5K 0.03% 390
2024
Q2 		$592K Sell
19,358
-26,787
-58% -$868K 0.02% 451
2024
Q1 		$1.34M Sell
46,145
-9,233
-17% -$259K 0.05% 275
2023
Q4 		$1.53M Buy
55,378
+20,002
+57% +$457K 0.07% 241
2023
Q3 		$793K Sell
35,376
-337
-0.9% -$12.5K 0.04% 339
2023
Q2 		$1.45M Buy
35,713
+6,392
+22% +$313K 0.08% 221
2023
Q1 		$1.42M Buy
+29,321
New +$1.34M 0.09% 195

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Profund Advisors's PTCT Position: Q2 2026 in Review

Profund Advisors reduced its PTC Therapeutics (PTCT) stake by 31% in Q2 2026, selling an estimated $748K and leaving 22,973 shares worth $1.87M. The position accounts for 0.05% of the portfolio, ranked #211.

Profund Advisors first reported a position in PTCT in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.42M in Q4 2025. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Profund Advisors held 22,973 shares of PTC Therapeutics worth $1.87M as of Q2 2026.
  • Profund Advisors sold 10,353 PTC Therapeutics shares in Q2 2026, an estimated $748K.
  • PTC Therapeutics made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #211 holding.
  • Profund Advisors first reported a position in PTC Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's PTC Therapeutics position peaked at $2.42M in Q4 2025.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.